Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.05 (-7.21%)
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Metagenomi Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
No pe ratio figures for Metagenomi Therapeutics
Metagenomi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?